Biocon Biologics is a subsidiary of Biocon with a focus on Biocon’s Biosimilars business. It has one of the largest global biosimilars portfolios spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other biologics for oncology, immunology and other therapeutic areas. We are well positioned to offer lowered costs and increasing access to this highly innovative class of drugs. The demand for biosimilars is set to grow as patents expire on leading biologics and patients demand lower priced drugs.